PQ6 Stock Chart & Stats
€0.44
<€0.01(0.91%)
At close: 4:00 PM EDT
€0.44
<€0.01(0.91%)
Day’s Range― - ―
52-Week Range€0.11 - €0.52
Previous CloseN/A
Volume0.00
Average Volume (3M)546.00
Market Cap
€246.99M
Enterprise Value€284.34
Total Cash (Recent Filing)€11.02M
Total Debt (Recent Filing)€707.00K
Price to Earnings (P/E)―
Beta1.18
Next Earnings
Mar 02, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding477,054,960
10 Day Avg. Volume0
30 Day Avg. Volume546
Financial Highlights & Ratios
PEG Ratio1.43
Price to Book (P/B)21.33
Price to Sales (P/S)24.38
P/FCF Ratio-84.01
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)<0.01
Revenue Forecast (FY)€14.76M
Bulls Say, Bears Say
Bulls Say
Dendrimer Platform And Licensing ModelStarpharma has a differentiated dendrimer technology platform spanning therapeutic drug delivery and commercial healthcare products. This creates multiple routes to monetisation, including licensing, milestones, royalties, product sales and distribution, supporting strategic optionality over time.
Substantially Reduced DebtThe sharp reduction in debt materially lowers financial risk and interest-related pressure. A lightly leveraged balance sheet gives Starpharma greater flexibility to direct resources toward development and commercialisation, while reducing refinancing exposure during periods of continued operating losses.
Improved Cash BurnAlthough cash generation remains negative, the marked improvement in operating and free cash flow indicates better cash discipline or reduced funding needs than in prior years. If sustained, this trend could extend the company’s financial runway and lessen pressure on future funding.
Bears Say
Persistent Operating LossesStarpharma has not yet demonstrated operating profitability, despite generating A$10.4m of gross profit in 2026. Persistent EBIT, EBITDA and net losses limit internal funding capacity and make successful commercial execution essential to establishing durable earnings power.
Ongoing Negative Free Cash FlowRepeated negative operating and free cash flow shows that the business remains unable to self-fund its activities. Even with improved 2026 cash burn, continued outflows may require additional funding unless profitability or recurring commercial receipts improve materially.
Eroding Equity And Asset BaseThe substantial decline in equity, alongside a shrinking asset base, reflects the cumulative effect of losses and cash consumption. This reduces financial resilience and limits the resources available to absorb setbacks or fund development without further capital support.
Starpharma Holdings Limited News
PQ6 FAQ
What was Starpharma Holdings Limited’s price range in the past 12 months?
Starpharma Holdings Limited lowest stock price was €0.11 and its highest was €0.52 in the past 12 months.
What is Starpharma Holdings Limited’s market cap?
Starpharma Holdings Limited’s market cap is €246.99M.
When is Starpharma Holdings Limited’s upcoming earnings report date?
Starpharma Holdings Limited’s upcoming earnings report date is Mar 02, 2027 which is in 155 days.
How were Starpharma Holdings Limited’s earnings last quarter?
Starpharma Holdings Limited released its earnings results on Aug 25, 2026. The company reported -€0.012 earnings per share for the quarter.
Is Starpharma Holdings Limited overvalued?
According to Wall Street analysts Starpharma Holdings Limited’s price is currently Overvalued.
Does Starpharma Holdings Limited pay dividends?
Starpharma Holdings Limited does not currently pay dividends.
What is Starpharma Holdings Limited’s EPS estimate?
Starpharma Holdings Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Starpharma Holdings Limited have?
Starpharma Holdings Limited has 477,054,960 shares outstanding.
What happened to Starpharma Holdings Limited’s price movement after its last earnings report?
Starpharma Holdings Limited reported an EPS of -€0.012 in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Starpharma Holdings Limited?
Currently, no hedge funds are holding shares in DE:PQ6
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Starpharma Holdings Limited Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
DE:PQ6 Sentiment 100%
Sector Average 64%
Sector Average 64%
Insider Transactions
Bought Shares
Worth €191.8K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
398.94%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-20.92%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Starpharma Holdings Limited
Starpharma Holdings Limited is a biopharmaceutical enterprise focused on the research, development, and global commercialization of dendrimer-based products for the pharmaceutical, life sciences, and other industries. Its current offerings include VivaGel, a non-antibiotic treatment and preventative measure for bacterial vaginosis. The company also provides the antiviral VivaGel condom and VIRALEZE, an antiviral nasal spray. Furthermore, Starpharma is actively progressing its DEP (dendrimer drug delivery) technology platform. This platform supports multiple oncology candidates in clinical development, such as DEP docetaxel (Phase 2), DEP cabazitaxel (Phase 2), DEP gemcitabine (Phase 1/2), and DEP irinotecan (Phase 2), all aimed at treating cancer. The DEP technology is also being applied to radiotheranostics for cancer diagnosis and therapy, Antibody Drug Conjugates (including DEP HER-2 ADC), and non-oncology programs. Additionally, DEP AZD0466 is currently in Phase 1/2 clinical trials for haematological malignancies. Founded in 1996, the company maintains its headquarters in Abbotsford, Australia.
Technical Analysis
Immutep Ltd
―
Dimerix Limited
―
AnteoTech Ltd
―
Botanix Pharmaceuticals Limited
―
Recce Pharmaceuticals Ltd.
―